EMA Extends Amputation Investigation to All SGLT2 InhibitorsEMA Extends Amputation Investigation to All SGLT2 Inhibitors

In a revision of its April 2016 notice regarding canagliflozin and amputations, the EMA's Pharmacovigilance Risk Assessment Committee is now investigating all drugs in the class. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news